Skip to main content
. 2024 Jan 2;15:48. doi: 10.1038/s41467-023-44308-6

Fig. 7. Several vaccination approaches enhance CD3xTRP1 therapy.

Fig. 7

Kaplan-Meier curves for indicated groups of B16F10-bearing mice receiving OVA vaccination (a), or Gp100 vaccination (b) according to the treatment schedule described in Fig. 1d. Numbers indicate fractions of surviving mice at the end of the experiment. c Treatment schedule for mice pre-inoculated with LCMV-Armstrong (for Fig. 7d) or HKx31 influenza virus (for Supplementary Fig. 10), followed by B16F10 inoculation. Indicated are administration of LCMV Gp34 peptide vaccination (for Fig. 7d), or inactivated HKx31 influenza virus (for Supplementary Fig. 10) and CD3xTRP1. d Kaplan-Meier curves for indicated groups receiving LCMV/Gp34 treatments. Numbers indicate fractions of surviving mice at the end of the experiment. e Kaplan-Meier curves for indicated groups of MC38-TRP1-bearing mice receiving OVA or Rpl18 vaccination in combination with CD3xTRP1 according to the treatment schedule in Fig. 1d. Numbers indicate fractions of surviving mice at the end of the experiment. Significance was calculated using Mantel-Cox Log-Rank tests (a, b, d, e). Source data are provided as a Source Data file.